Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18033553 | 0.90 | ESR2 (0.67) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL6188337 | 0.87 | ESR2 (0.50) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL24761144 | 0.85 | ESR2 (0.56) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL4039631 | 0.84 | ESR2 (0.56) | ESR2NR1H2GPR119STS | |
| SCHEMBL3874588 | 0.82 | ESR2 (0.53) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL18022672 | 0.82 | ESR2 (0.53) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL3722059 | 0.82 | ESR2 (0.53) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL3872624 | 0.81 | ESR2 (0.52) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL3873760 | 0.81 | ABHD6 (0.53) | ESR2HDAC1NR1H2DDB1CRBN | |
| SCHEMBL6867369 | 0.81 | RYR2 (0.54) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1119562-B1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | SMITHKLINE BEECHAM P.L.C. | 2003-08-21 | — | — | US | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-1119562-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021950-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | OPRD1, DRD3, OPRM1 | ESR2 585/4885HDAC1 1709/4885NR1H2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.